失代偿期丙肝肝硬化患者并发脾亢进消除后的抗病毒治疗
2016-05-14禹蔚琴
禹蔚琴

[摘要] 目的 探讨失代偿期丙肝肝硬化患者并发脾亢进消除后的抗病毒治疗。 方法 整群选取该院2010年2月—2015年3月收治的42例失代偿期丙肝肝硬化患者并发脾亢进患者为研究对象,接受脾栓塞手术或者脾切除手术,在脾功能亢进改善时间3月后,对患者进行皮下注射90μg 或135 μg 聚乙二醇干扰素(Peg-IFN)α-2a,并口服利巴韦林联合,观察患者的抗病毒治疗疗效。 结果 治疗前后患者相关指标的比较具有统计学意义(P<0.05)。患者接受用药后,早期的应答率为54.76%。在患者接受抗病毒治疗后,患者的血液ALT复常率为85.71%,治疗的终点应答率为83.33%,患者的持续治疗应答率为61.90%,要明显高于早期应答率(P<0.05)。患者在治疗期间的不良反应发生率为100%。 结论 皮下注射聚乙二醇干扰素(Peg-IFN)α-2a,联合口服利巴韦林,是失代偿期丙肝肝硬化患者并发症消除后的抗病毒治疗的有效手段,值得考虑应用。
[Abstract] Objective To discuss the antivirus treatment for patients with hepatitis C cirrhosis at decompensated stage after elimination of complicated hypersplenism. Methods 42 cases of patients with hepatitis C cirrhosis at decompensated stage complicated by hypersplenism admitted and treated in our hospital from February 2010 to March 2015 were selected as the research object and were treated with splenic embolization operation and splenectomy operation, after 3 months of improvement of hypersplenism, the patients were given subcutaneous injection of 90μg or 135 μg pegylated interferons (Peg-IFN)α-2a and oral administration of ribavirin, the antivirus treatment curative effect of the patients was observed. Results The comparison of related index before and after treatment was statistically significant(P<0.05), after medication, the early response rate was 54.76%, after the antivirus treatment, the normalizing rate of blood ALT of patients was 85.71%,and the treatment terminal response rate was 83.33%,the sustained treatment response rate of patients was 61.90%,which was obviously higher than early response rate(P<0.05),the incidence of adverse reactions of patients during treatment was 100%. Conclusion Subcutaneous injection of pegylated interferons(Peg-IFN)α-2a combined with oral administration of ribavirin is an effective means of antivirus treatment for patients with hepatitis C cirrhosis at decompensated stage after elimination of complication, which is worth consideration and application.
[Key words] At decompensated stage; Hepatitis C cirrhosis; Antivirus
婴幼儿是婴儿和幼儿的统称,一般是指0~3岁的小龄孩子[1]。婴儿与幼儿之间有莫大的联系,婴幼儿身体组织器官功能发育尚未成熟,器官功能与生活适应能力都比较差,并且免疫能力也未健全,抵抗力较差,极易发生细菌感染在临床中如果护理不周会有比较高的死亡率[2]。随机选取2014年8月—2015年7月该院收治的80例婴幼儿重症细菌感染患者,该研究就亚胺培南治疗婴幼儿重症细菌感染的临床治疗效果以及不良反应进行统计分析,现报道如下。
1 资料与方法
1.1 一般资料
随机选择2014年8月—2015年7月该院收治的80例婴幼儿重症细菌感染患者,随机分为两组,每组40例。对照组中男19例,女21例,年龄0~3岁,平均年龄(1.38±0.38)岁,采用美罗培南治疗,不包括脑膜炎患儿;观察组中男20例,女20例,年龄0~3岁,平均年龄(1.52±0.71)岁,采用亚胺培南西司他丁治疗。两组患儿一般资料差异无统计学意义(P>0.05),具有可对比性。
1.2 方法
对照组患者采用美罗培南(国药准字00202H194),10~20 mg/kg,8 h/次,静脉滴注。
观察组患者选用亚胺培南西司他丁钠(杭州默沙东制药有限公司,国药准字H20094023)治疗,15 mg/kg,6 h/次,静脉滴注。……p>
